Company
NovoCure Limited
Headquarters: Saint Helier, Jersey
Employees: 1,167
CEO: Mr. Asaf Danziger
Market Cap
$2.85 Billion
USD as of Jan. 1, 2025
NovoCure Limited Categories
United Kingdom Healthcare Medical Instruments & SuppliesUnited Kingdom Healthcare United Kingdom Medical Instruments & Supplies
Top Competitors by Market Capitalization
Industry: Medical Instruments & Supplies
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $216.79 B |
| EssilorLuxottica SA | $116.96 B |
| Becton, Dickinson and Company | $69.74 B |
| HOYA Corp | $45.26 B |
| Alcon Inc. | $41.55 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $577.7 M |
| EBITDA | $-140,611,008 |
| Gross Profit TTM | $442.3 M |
| Profit Margin | -25.93% |
| Operating Margin | -20.69% |
| Quarterly Revenue Growth | 21.80% |
Stocks & Indices
NovoCure Limited has the following listings and related stock indices.
Stock: NASDAQ: NVCR wb_incandescent
Stock: FSX: 38 wb_incandescent